AU2001281250A1 - (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production - Google Patents

(hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production

Info

Publication number
AU2001281250A1
AU2001281250A1 AU2001281250A AU8125001A AU2001281250A1 AU 2001281250 A1 AU2001281250 A1 AU 2001281250A1 AU 2001281250 A AU2001281250 A AU 2001281250A AU 8125001 A AU8125001 A AU 8125001A AU 2001281250 A1 AU2001281250 A1 AU 2001281250A1
Authority
AU
Australia
Prior art keywords
ureas
alzheimer
hydroxyethyl
inhibitors
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281250A
Inventor
Dennis J. Selkoe
Michael S. Wolfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2001281250A1 publication Critical patent/AU2001281250A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
AU2001281250A 2000-08-11 2001-08-10 (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production Abandoned AU2001281250A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22504300P 2000-08-11 2000-08-11
US60225043 2000-08-11
PCT/US2001/025267 WO2002014264A2 (en) 2000-08-11 2001-08-10 (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production

Publications (1)

Publication Number Publication Date
AU2001281250A1 true AU2001281250A1 (en) 2002-02-25

Family

ID=22843279

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281250A Abandoned AU2001281250A1 (en) 2000-08-11 2001-08-10 (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production

Country Status (3)

Country Link
US (1) US6696488B2 (en)
AU (1) AU2001281250A1 (en)
WO (1) WO2002014264A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60045005D1 (en) 1999-06-28 2010-11-04 Oklahoma Med Res Found INHIBITORS OF MEMAPSIN 2 AND ITS USE
AP2004003049A0 (en) * 2001-11-08 2004-06-30 Elan Pharm Inc N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives.
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
PE20040762A1 (en) * 2002-11-27 2004-11-06 Elan Pharm Inc SUBSTITUTED UREAS AND CARBAMATES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CA2618508A1 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
EP2643299B1 (en) 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
WO2012174552A2 (en) * 2011-06-17 2012-12-20 Virobay, Inc. Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
CA3107352A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
CN113164563A (en) 2018-07-23 2021-07-23 因柯利尔疗法公司 Method of treatment of neurological disorders
EP3952947A1 (en) 2019-04-11 2022-02-16 Enclear Therapies, Inc. Methods of amelioration of cerebrospinal fluid and devices and systems therefor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2331926A (en) 1941-03-29 1943-10-19 Sharples Chemicals Inc Resinous condensation product and manufacture thereof
US2344259A (en) 1941-04-14 1944-03-14 Arnold Hoffman & Co Inc Alkali salts of fatty carbamino compounds
CH440252A (en) 1964-04-24 1967-07-31 Wander Ag Dr A Process for the production of new urea derivatives
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
US4757050A (en) 1985-12-23 1988-07-12 E. R. Squibb Sons, Inc. Ureido renin inhibitors
CA1297631C (en) 1985-12-23 1992-03-17 Sesha I. Natarajan Ureido renin inhibitors
DE3635907A1 (en) 1986-10-22 1988-04-28 Merck Patent Gmbh HYDROXY AMINO ACID DERIVATIVES
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5475013A (en) 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
DK0554400T3 (en) * 1990-11-19 1998-02-16 Monsanto Co Retroviral protease inhibitors
US5830897A (en) 1992-08-27 1998-11-03 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5604198A (en) 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
UA49803C2 (en) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Method for treatment of retrovirus infections
US6017887A (en) 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
CA2264485A1 (en) 1996-09-06 1998-03-12 St. Elizabeth's Medical Center Of Boston, Inc. Gata-6 transcription factor: compositions and methods
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US6114312A (en) 1997-03-07 2000-09-05 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
US5977174A (en) 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
AU3771700A (en) 1999-03-24 2000-10-09 Regents Of The University Of California, The Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease

Also Published As

Publication number Publication date
US20020111365A1 (en) 2002-08-15
WO2002014264A2 (en) 2002-02-21
US6696488B2 (en) 2004-02-24
WO2002014264A3 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
AUPP868599A0 (en) Production of isoflavone derivatives
AU2002307432A1 (en) Production of alpha-lipoic acid
AU6487600A (en) Process for production of an etheralcohol
AU2001281250A1 (en) (hydroxyethyl)ureas as inhibitors of alzheimer&#39;s beta-amyloid production
AU2001269063A1 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
AU2002213422A1 (en) Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
AU2002235326A1 (en) Processes for large scale production of tetrapyrroles
AU6359400A (en) Production of aliphatic fluorocarbons
AU2001244692A1 (en) Novel crystal form of pyrrolidylthiocarbapenem derivative
AU2001277545A1 (en) Process for the production of 2-hydroxy-4-methylmercaptobutyric acid
HUP0300475A3 (en) Novel stable crystal of thiazolidinedione derivative and process for producing the same
AU7445100A (en) Sebum production inhibitors
AU2001265935A1 (en) Production of biohydrolysates
AU2001277801A1 (en) Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols
EP1243564A3 (en) Process for preventing formation of scale
AU1720501A (en) Methods of producing novel enzymes
AU2001277632A1 (en) Process for the production of 3-hydroxypropanal
AU2002237704A1 (en) Methods for the stereoselective synthesis of substituted piperidines
AU2002234066A1 (en) Process for the production of amides
AU2002229149A1 (en) Process for producing hydrazinomonosaccharide derivatives and use thereof
AU2001225523A1 (en) Novel arylpropionaldehyde derivatives and production and use of the same
AU2001220267A1 (en) Novel 1beta-methylcarbapenem derivatives and process of preparation thereof
AU6565000A (en) Production of silica particles
AU5109600A (en) Process for the production of 2-pyridylpyridine derivatives
AU4291901A (en) Process for the production of 2-hydroxyethylmaleimide and the product obtained by the process